Company intelligence / Profile preview

MukoCell GmbH

Dortmund, Nordrhein-Westfalen, Germanymukocell.com ↗

Ownership: Private
Employees: ~7
Development stage: Commercial

Overview

MukoCell therapy has shown safety and effectiveness in a 36-month follow-up period. It eliminates the need for tissue grafting from the mouth and associated complications. The therapy is currently offered to more than 200 patients by 10 specialized clinics in Germany[5].

Therapeutic areas: Men's Health
Modalities: Autologous cell therapyTissue-engineered products
Industry: Biotech

Drug pipeline

1 asset

MukoCell

Unknown

Partnerships

Co.don (manufacturing partner)[3]

Beyond the preview

Go deeper on MukoCell GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MukoCell GmbH.

Explore the full profile